Axogen Q1 2024 Adj EPS $(0.06) Beats $(0.07) Estimate, Sales $41.378M Miss $41.964M Estimate
Portfolio Pulse from Benzinga Newsdesk
Axogen (NASDAQ:AXGN) reported Q1 2024 adjusted EPS of $(0.06), beating the $(0.07) estimate, but missed sales estimates with $41.378M against the expected $41.964M. This represents a 40% improvement in EPS and a 12.86% increase in sales year-over-year.
May 02, 2024 | 11:18 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Axogen reported a smaller-than-expected Q1 2024 loss per share but missed on sales estimates, showing both EPS improvement and sales growth year-over-year.
The mixed results with an EPS beat but a slight miss on sales forecasts could lead to a neutral short-term impact on AXGN's stock price. The improvement in EPS year-over-year is positive, but the sales miss, albeit small, may temper investor enthusiasm.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100